Literature DB >> 21692949

Acute hepatitis C infection lowers serum lipid levels.

K E Corey1, J Mendez-Navarro, L L Barlow, V Patwardhan, H Zheng, A Y Kim, G M Lauer, R T Chung.   

Abstract

Chronic hepatitis C infection is associated with hypolipidaemia that resolves with viral clearance. Lipid levels in a subgroup of patients rebound to levels that may increase the risk of coronary heart disease. The impact of acute hepatitis C infection and its clearance on lipid levels is unknown. We undertook a retrospective evaluation of subjects with acute hepatitis C infection evaluating lipid levels before, during and following acute infection. Thirty-eight subjects with acute hepatitis C infection had lipid levels available. Twelve patients had pre-infection and intra-infection lipid levels available. Cholesterol (197.8-152.4 mg/dL, P = 0.025), low-density lipoprotein (LDL) (116.1-76.3 mg/dL, P = 0.001) and non-high-density lipoprotein (non-HDL) cholesterol (164.0-122.7 mg/dL, P = 0.007) decreased dramatically during acute hepatitis C virus infection. Nineteen patients who achieved viral clearance had lipid levels available during infection and following resolution of infection. In these patients, cholesterol (145.0-176.0 mg/dL, P = 0.01), LDL (87.0-110.1 P = 0.0046) and non-HDL cholesterol (108.6-133.6 mg/dL, P = 0.008) increased significantly. No change was seen in patients who developed chronic infection. Four patients had lipid levels before, during and following resolution of infections and had increased postinfection LDL, cholesterol and non-HDL cholesterol from pre-infection levels, indicating acute infection may be associated with an increase in postinfection lipid levels and may confer an increased risk of coronary heart disease. Acute hepatitis C infection results in hypolipidaemia with decreased LDL, cholesterol and non-HDL cholesterol levels that increase following infection resolution. Levels may increase above pre-infection baseline lipid levels and should be monitored.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21692949      PMCID: PMC3739431          DOI: 10.1111/j.1365-2893.2011.01434.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  17 in total

1.  Blood lipids of patients with chronic hepatitis: differences related to viral etiology.

Authors:  C Fabris; E Federico; G Soardo; E Falleti; M Pirisi
Journal:  Clin Chim Acta       Date:  1997-05-28       Impact factor: 3.786

2.  Bone mineral density in long-term survivors following pediatric liver transplantation.

Authors:  Stephen L Guthery; John F Pohl; John C Bucuvalas; Maria H Alonso; Frederick C Ryckman; William F Balistreri; James E Heubi
Journal:  Liver Transpl       Date:  2003-04       Impact factor: 5.799

3.  Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor.

Authors:  V Agnello; G Abel; M Elfahal; G B Knight; Q X Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

4.  In vitro interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs.

Authors:  Sabina Wunschmann; Hubert M Muller; Christopher S Stipp; Martin E Hemler; Jack T Stapleton
Journal:  J Infect Dis       Date:  2006-09-08       Impact factor: 5.226

5.  Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins.

Authors:  Olivier Diaz; François Delers; Marianne Maynard; Sylvie Demignot; Fabien Zoulim; Jean Chambaz; Christian Trépo; Vincent Lotteau; Patrice André
Journal:  J Gen Virol       Date:  2006-10       Impact factor: 3.891

6.  Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis.

Authors:  Silvia Mirandola; Stefano Realdon; Jahangir Iqbal; Martina Gerotto; Francesca Dal Pero; Gladis Bortoletto; Moira Marcolongo; Alessandro Vario; Christian Datz; M Mahmood Hussain; Alfredo Alberti
Journal:  Gastroenterology       Date:  2006-03-06       Impact factor: 22.682

7.  A functional ABCA1 gene variant is associated with low HDL-cholesterol levels and shows evidence of positive selection in Native Americans.

Authors:  Víctor Acuña-Alonzo; Teresa Flores-Dorantes; Janine K Kruit; Teresa Villarreal-Molina; Olimpia Arellano-Campos; Tábita Hünemeier; Andrés Moreno-Estrada; Ma Guadalupe Ortiz-López; Hugo Villamil-Ramírez; Paola León-Mimila; Marisela Villalobos-Comparan; Leonor Jacobo-Albavera; Salvador Ramírez-Jiménez; Martin Sikora; Lin-Hua Zhang; Terry D Pape; Ma de Angeles Granados-Silvestre; Isela Montufar-Robles; Ana M Tito-Alvarez; Camilo Zurita-Salinas; José Bustos-Arriaga; Leticia Cedillo-Barrón; Celta Gómez-Trejo; Rodrigo Barquera-Lozano; Joao P Vieira-Filho; Julio Granados; Sandra Romero-Hidalgo; Adriana Huertas-Vázquez; Antonio González-Martín; Amaya Gorostiza; Sandro L Bonatto; Maricela Rodríguez-Cruz; Li Wang; Teresa Tusié-Luna; Carlos A Aguilar-Salinas; Ruben Lisker; Regina S Moises; Marta Menjivar; Francisco M Salzano; William C Knowler; M Cátira Bortolini; Michael R Hayden; Leslie J Baier; Samuel Canizales-Quinteros
Journal:  Hum Mol Genet       Date:  2010-04-23       Impact factor: 6.150

8.  Characterization of low- and very-low-density hepatitis C virus RNA-containing particles.

Authors:  P André; F Komurian-Pradel; S Deforges; M Perret; J L Berland; M Sodoyer; S Pol; C Bréchot; G Paranhos-Baccalà; V Lotteau
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

Authors:  J Stamler; D Wentworth; J D Neaton
Journal:  JAMA       Date:  1986-11-28       Impact factor: 56.272

10.  Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication.

Authors:  Chunfu Wang; Michael Gale; Brian C Keller; Hua Huang; Michael S Brown; Joseph L Goldstein; Jin Ye
Journal:  Mol Cell       Date:  2005-05-13       Impact factor: 17.970

View more
  9 in total

Review 1.  Treatment of Dyslipidemia in Common Liver Diseases.

Authors:  Elizabeth K Speliotes; Maya Balakrishnan; Lawrence S Friedman; Kathleen E Corey
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04-21       Impact factor: 11.382

Review 2.  Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes.

Authors:  Tracey G Simon; Adeel A Butt
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

Review 3.  Lipids and HCV.

Authors:  M F Bassendine; D A Sheridan; S H Bridge; D J Felmlee; R D G Neely
Journal:  Semin Immunopathol       Date:  2012-10-31       Impact factor: 9.623

4.  Association of Serum Lipids with Hepatic Steatosis, Stage of Liver Fibrosis and Viral Load in Chronic Hepatitis C.

Authors:  Ivan Valkov; Radina Ivanova; Assen Alexiev; Krasimir Antonov; Lyudmila Mateva
Journal:  J Clin Diagn Res       Date:  2017-08-01

Review 5.  Hepatitis C Virus Uses Host Lipids to Its Own Advantage.

Authors:  Malgorzata Sidorkiewicz
Journal:  Metabolites       Date:  2021-04-27

6.  Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum 1H-NMR Spectroscopy.

Authors:  Nieves Embade; Zoe Mariño; Tammo Diercks; Ainara Cano; Sabela Lens; Diana Cabrera; Miquel Navasa; Juan M Falcón-Pérez; Joan Caballería; Azucena Castro; Jaume Bosch; José M Mato; Oscar Millet
Journal:  PLoS One       Date:  2016-05-09       Impact factor: 3.240

7.  1H NMR-based serum metabolomics reveals erythromycin-induced liver toxicity in albino Wistar rats.

Authors:  Atul Rawat; Durgesh Dubey; Anupam Guleria; Umesh Kumar; Amit K Keshari; Swati Chaturvedi; Anand Prakash; Sudipta Saha; Dinesh Kumar
Journal:  J Pharm Bioallied Sci       Date:  2016 Oct-Dec

8.  Some considerations about cardiac toxicity of combination therapy for chronic hepatitis C.

Authors:  Reza Karbasi-Afshar; Amin Saburi
Journal:  Hepat Mon       Date:  2013-05-14       Impact factor: 0.660

9.  Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES.

Authors:  Adeel A Butt; Peng Yan; Tracey G Simon; Raymond T Chung; Abdul-Badi Abou-Samra
Journal:  BMC Infect Dis       Date:  2015-11-11       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.